These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2143501)

  • 1. Hypersensitivity reactions to trimetrexate.
    Grem JL; King SA; Costanza ME; Brown TD
    Invest New Drugs; 1990 May; 8(2):211-4. PubMed ID: 2143501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
    Licht JD; Gonin R; Antman KH
    Cancer Chemother Pharmacol; 1991; 28(3):223-5. PubMed ID: 1830249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of severe or life-threatening toxic effects from trimetrexate.
    Grem JL; Ellenberg SS; King SA; Shoemaker DD
    J Natl Cancer Inst; 1988 Oct; 80(16):1313-8. PubMed ID: 2971817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
    Iscoe NA; Eisenhauer EA; Bodurtha AJ
    Invest New Drugs; 1990 Feb; 8(1):121-3. PubMed ID: 2140563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
    Odujinrin O; Goldberg D; Doroshow J; Leong L; Margolin K; Grove W; Carr B; Akman S
    Med Pediatr Oncol; 1990; 18(1):49-52. PubMed ID: 2136764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse Pneumocystis carinii pneumonitis and adverse reaction to current therapy in patients with AIDS: trimetrexate as an alternative.
    Faber HJ; Sprenger HG; Weits J
    Neth J Med; 1990 Aug; 37(1-2):69-74. PubMed ID: 2145521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
    Allegra CJ; Chabner BA; Tuazon CU; Ogata-Arakaki D; Baird B; Drake JC; Simmons JT; Lack EE; Shelhamer JH; Balis F
    N Engl J Med; 1987 Oct; 317(16):978-85. PubMed ID: 2958710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetrexate: predictors of severe or life-threatening toxic effects.
    Eisenhauer EA; Zee BC; Pater JL; Walsh WR
    J Natl Cancer Inst; 1988 Oct; 80(16):1318-22. PubMed ID: 2971818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding trimetrexate toxicity.
    Donehower RC
    J Natl Cancer Inst; 1988 Oct; 80(16):1268-9. PubMed ID: 2971816
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties.
    Lin JT; Bertino JR
    Cancer Treat Res; 1989; 42():79-95. PubMed ID: 2577109
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
    Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
    Kovacs JA; Allegra CJ; Kennedy S; Swan JC; Drake J; Parrillo JE; Chabner B; Masur H
    Am J Trop Med Hyg; 1988 Nov; 39(5):491-6. PubMed ID: 2973755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
    Sternberg CN; Yagoda A; Scher H; Bosl G; Dershaw D; Rosado K; Houston C; Rosenbluth R; Vinciguerra V; Boselli B
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):753-4. PubMed ID: 2523810
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS).
    Allegra CJ; Chabner BA; Tuazon CU; Ogata-Arakaki D; Baird B; Drake JC; Masur H
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):46-9. PubMed ID: 2966985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties.
    Lin JT; Bertino JR
    Cancer Invest; 1991; 9(2):159-72. PubMed ID: 1830825
    [No Abstract]   [Full Text] [Related]  

  • 16. Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.
    Leiby JM
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):27-31. PubMed ID: 2966983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimetrexate: a second generation folate antagonist in clinical trial.
    Lin JT; Bertino JR
    J Clin Oncol; 1987 Dec; 5(12):2032-40. PubMed ID: 2960788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia.
    Sattler FR; Allegra CJ; Verdegem TD; Akil B; Tuazon CU; Hughlett C; Ogata-Arakaki D; Feinberg J; Shelhamer J; Lane HC
    J Infect Dis; 1990 Jan; 161(1):91-6. PubMed ID: 2136905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.
    Cantwell BM; Macaulay V; Harris AL; Kaye SB; Smith IE; Milsted RA; Calvert AH
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):733-6. PubMed ID: 3383974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
    Carlson RW; Doroshow JH; Odujinrin OO; Flam MS; Malec M; Lamborn KR
    Invest New Drugs; 1990 Nov; 8(4):387-9. PubMed ID: 2150672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.